Luteinizing Hormone-releasing Hormone Antagonists in Gynecology

J. Engel, K. Diedrich
In: Peptides and Non Peptides of Oncologic and Neuroendocrine Relevance · 2003 · pp. 29–38 · doi:10.1007/978-88-470-2085-6_3 · W1021307608
book-chapter OA: closed CC0
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by claude@2026-06+body, 2026-06-10 ⓘ

LHRH antagonists, developed after LHRH superagonists, were found to cause pharmacological hypophysectomy by depleting pituitary LHRH receptors.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 ⓘ

This paper is a narrative review describing the development and gynecologic use of luteinizing hormone–releasing hormone (LHRH/GnRH) antagonists, tracing advances from LHRH structural elucidation and engineered superagonists to receptor-based pharmacology in which antagonists prevent the LH surge and can cause pharmacologic suppression via pituitary receptor depletion. It outlines that after initial FSH/LH “flare-up” seen with agonists, the mechanism of receptor depletion underlies downstream hypophysectomy-like effects, and it discusses early evidence and subsequent work on antagonist potency, kinetics, and pituitary receptor regulation. The main limitation is that, as a review centered on development and general gynecologic applications, it does not present a unified new dataset or a single systematic method for synthesizing efficacy across indications. Relevance to endometriosis: the reference list includes work on GnRH analog hormonal therapy and add-back strategies for endometriosis (e.g., Fränke et al. on GnRH agonist plus add-back), and it also cites reviews specifically addressing the use of GnRH antagonists in endometriosis, though the paper’s main focus is broader on LHRH antagonists in gynecology.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (57)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK